Evidence map›Paper›PMID 41458255›Full record

ReviewDrug design, development and therapy2025

Endoplasmic Reticulum-Targeting Natural Compounds: A Novel Frontier in Alleviating Liver Fibrosis.

Chengrong Huang, Wei Hu, Jia Qi, Bolun Su, Hongrui Yan, Yi Zhun Zhu

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chengrong Huang *School of Pharmacy, Macau University of Science and Technology, Macau SAR, 999078, People's Republic of China.
Wei Hu *School of Pharmacy, Macau University of Science and Technology, Macau SAR, 999078, People's Republic of China.
Jia QiDepartment of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, People's Republic of China.
Bolun SuLaboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, 999078, People's Republic of China.
Hongrui YanLaboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, 999078, People's Republic of China.
Yi Zhun ZhuSchool of Pharmacy, Macau University of Science and Technology, Macau SAR, 999078, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis, a reversible yet critical stage in chronic liver disease progression, poses a significant global health burden with limited therapeutic options. This review comprehensively explores the molecular mechanisms of endoplasmic reticulum (ER) stress and its dual role in both parenchymal and non-parenchymal cells during liver fibrosis, alongside the therapeutic potential of natural compounds that target ER stress to alleviate fibrosis. Emerging evidence underscores ER stress and oxidative stress as pivotal drivers of hepatic fibrogenesis, primarily through activating hepatic stellate cells (HSCs). We systematically summarize a wide array of natural compounds, from polyphenols to terpenoids, that demonstrate potent anti-fibrotic effects by either ameliorating maladaptive ER stress in hepatocytes or selectively inducing pro-apoptotic ER stress in activated HSCs. Despite their promise, the clinical translation of these compounds is hampered by poor bioavailability and non-specific targeting. We highlight the groundbreaking potential of biomimetic nano-delivery systems, such as cell membrane-camouflaged nanoparticles, to overcome these barriers, offering precise targeting and enhanced therapeutic efficacy. Finally, we discuss current challenges and future directions, advocating for interdisciplinary efforts to advance ER stress-targeting strategies from bench to bedside.

Indexed as

Biological ProductsEndoplasmic ReticulumEndoplasmic Reticulum StressLiver CirrhosisAnimalsHepatic Stellate CellsHumansBiological Productsendoplasmic reticulum stressliver fibrosisnatural compoundstargeted therapyunfolded protein response

Identifiers

PMID41458255
PMCPMC12743463

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.